

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet 1 of 1

APPLICATION NO.: 09/921,655

ATTY. DOCKET NO.: M0925.70106US00

FILING DATE: August 3, 2001

CONFIRMATION NO.: 5833

APPLICANT: Michael H. Cardone et al.

GROUP ART UNIT: 1641

EXAMINER: Changhwa J. Cheu

**U.S. PATENT DOCUMENTS**

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		5,834,250		Wells et al.	11-10-1998

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
		CUNNINGHAM et al., "High-Resolution Epitope Mapping of hGH-Receptor Interactions By Alanine-Scanning Mutagenesis," <u>Science</u> , vol. 244, pp. 1081-1085 (1989)		
		AFZALPURKAP et al., "Identification Of Epitopes Of Monoclonal Antibodies To Porcine Zona Pellucida 3 $\beta$ Glycoprotein, A Homologue Of The Mouse/Human Sperm Receptor," <u>American Journal of Reproductive Immunology</u> , vol. 38, pp. 26-32 (1997)		

EXAMINER

DATE CONSIDERED

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).